logo
Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

WASHINGTON (AP) — Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following several patient deaths.
The decision, announced late Monday, comes just days after the company rebuffed FDA regulators in an extremely unusual decision that alarmed investors and analysts.
Sarepta CEO Doug Ingram said the company seeks a 'productive and positive' relationship with FDA and that 'maintaining that productive working relationship required this temporary suspension.'
The Cambridge, Massachusetts-based company said it would ' temporarily pause all shipments' of its gene therapy Elevidys for muscular dystrophy at the close of business Tuesday.
It's the latest in a series of highly irregular moves that have rocked company shares for weeks and forced it to lay off hundreds of staffers.
Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects boys and young men, resulting in early death. The one-time treatment was initially approved for boys age 4 and younger who could still walk. Last year, FDA expanded approval to older patients who are no longer able to walk.
The therapy was already under FDA scrutiny after two teenage boys died earlier this year from acute liver injury, a known side effect of the treatment. Then the company last week disclosed a third death with a different therapy: a 51-year-old patient who was enrolled in a company trial for a another form of muscular dystrophy.
FDA responded by asking the company to immediately halt all shipments of Elevidys.
Wall Street analysts said the company made the right move.
Defying the FDA would have 'irreparably damaged the company's relationship with FDA under the current leadership and administration,' TD Cowen analyst Ritu Baral told investors in a note Tuesday.
Baral estimated the pause in distribution would last three to six months.
The FDA has the authority to pull drugs from the market, but the process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply. Even in the rare cases when drugmakers haven't cooperated, the FDA has prevailed after public hearings and appeals.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand
Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand

Yahoo

time3 hours ago

  • Yahoo

Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand

By Siddhi Mahatole (Reuters) -Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for diagnostics products in its key market China to be hurt by changes to the country's reimbursement policy, sending the company's shares down nearly 10%. The medical equipment maker said that it now expects sales of its diagnostics products to grow in the low single digits this year, compared to its previous forecast of mid-single digit growth. Sales in China for diagnostic products declined by double digits in the second quarter. "We are now expecting a fairly meaningful pullback in the immunodiagnostics business in China," said CEO Prahlad Singh. China's hospital lab reimbursement policy changes tied to Diagnosis Related Groups (DRGs), have reduced demand for Revvity's higher-value diagnostic products and significantly hurt revenues. Medical device maker Abbott recently said its diagnostics division will be hit hardest, with a projected $700 million revenue impact in 2025 due to fading COVID test sales and pricing pressure from China's procurement program that buys medical devices in bulk at steep discounts. These changes, which took effect in late April, have prompted physicians to reduce their orders for multiplex diagnostic products used to test for multiple conditions simultaneously, Revvity said. Instead, healthcare providers are increasingly opting for single-plex tests - simpler, less comprehensive diagnostics that Revvity also supplies. Last week, larger peer Danaher reported improving conditions in China's pharma and biotech sectors, though it said diagnostics demand in the country remains under pressure. Thermo Fisher Scientific and Danaher both raised their annual profit forecasts. In contrast, Revvity said it expects adjusted profit per share for 2025 between $4.85 and $4.95, down from its previous projection of $4.90 to $5. Despite the hit, Revvity's second-quarter results aligned with industry peers and life sciences product sales reached $365.9 million, surpassing estimates of $353.9 million. The Massachusetts-based company expects full-year revenue of $2.84 billion to $2.88 billion, slightly above its prior forecast of $2.83 billion to $2.87 billion, aided by a weaker U.S. dollar. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Coinstar to offer Mastercard card
Coinstar to offer Mastercard card

Yahoo

time3 hours ago

  • Yahoo

Coinstar to offer Mastercard card

This story was originally published on Payments Dive. To receive daily news and insights, subscribe to our free daily Payments Dive newsletter. Dive Brief: Consumers who use Coinstar machines at grocery stores and other venues to convert their pocket change into another form of payment will soon be able to put the money on prepaid debit cards. That service will be available to the general public later this year, CEO Kevin McColly said in an interview last week. Coinstar is partnering with the network Mastercard to offer the cards, which will be issued as a virtual card, or customers can choose to have a physical card sent to them, McColly said. The company is testing the service in the market now with a limited group, he said. Pricing for the cards isn't set yet, the CEO said, explaining they may be offered for free, or there could be a fee. There is value to the company in offering it for free, and then allowing consumers to reuse it and gaining 'customer stickiness,' he said. Dive Insight: Coinstar operates 25,000 coin exchange kiosks at stores and other locations in eight countries in the U.S. and Europe, with some 50 million transactions annually. About 18,500 of those machines are in the United States. The new Mastercard debit card will add another option for consumers in terms of how they can convert their coins into other payment forms. 'We actually just soft launched it for friends and family a couple weeks ago, and our planned national rollout is sometime in very early Q4,' McColly said in an interview last Tuesday. The CEO explained how the soon-to-be-offered card will work: 'You can literally just go to the Coinstar machine, have a digital wallet on your phone, load it right there at the kiosk, and it's instantly available for you to go spend as a Mastercard debit card,' he said. The company generally charges a 12% fee if customers convert their coins to cash, via a receipt they take to cashiers at stores, but it also offers other ways to convert the coins without a fee. For instance, a customer can currently transfer the value to a Starbucks, Home Depot or other store gift card at the kiosk without paying a fee. For customers that may choose to load the value directly to their bank account, the financial institution may make the service available free-of-charge, or require a fee. A customer can also convert the money to bitcoin and load it onto a digital wallet. While McColly would not provide financial details, he said the company is profitable. The Bellevue, Washington-based company is owned by the private equity firm Apollo Global Management. Coinstar hasn't generally engaged in a lot of marketing in the past, and has instead relied mainly on its green machines at grocery stores to build brand awareness, McColly said. But for the launch of a new service, such as the Mastercard debit card, marketing will be a 'critical component,' he said. Mastercard didn't immediately have a comment on the new debit card relationship with Coinstar. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump trade policies less damaging than expected: IMF
Trump trade policies less damaging than expected: IMF

The Hill

time4 hours ago

  • The Hill

Trump trade policies less damaging than expected: IMF

President Trump's trade policies are less damaging than expected, with the International Monetary Fund (IMF) upgrading the projections of global economic growth for this year and 2026. The IMF, a Washington-based financial institution that works on facilitating international trade and sustained economic growth, projected a 3 percent global economic growth for 2025, 0.2 percentage points higher than the previous forecast from April, according to its Tuesday report. The organization, which consists of 190 member countries, is also projecting a 3.1 percent growth in 2026, 0.1 percentage point higher than the previous forecast. 'This reflects stronger-than-expected front-loading in anticipation of higher tariffs; lower average effective US tariff rates than announced in April; an improvement in financial conditions, including due to a weaker US dollar; and fiscal expansion in some major jurisdictions,' the IMF said in the new 12-page report. Similarly to the April findings, global headline inflation is expected to dip 4.2 percent this year and 3.6 percent next year. 'The overall picture hides notable cross-country differences, with forecasts predicting inflation will remain above target in the United States and be more subdued in other large economies,' the group said. Companies 'frontloading' imports before Trump's tariffs when into effect, along with the slight tumble of the U.S. dollar assisted in the growth of the world economy, IMF's chief economist Pierre-Olivier Gourinchas told The Financial Times. 'At the time of the April forecast, we had an effective tariff rate on [imports into the US] of 24 per cent,' Gourinchas said. 'We're now looking at an effective tariff rate of 17 per cent. While 17 is still much higher than where we were in January, there's been some easing of the tariff pressure.' China and the U.S. economies have received upgrades in the IMF's forecast, along with the United Kingdom, which will be the third-fastest-growing economy within the group of seven (G7) this year and in 2026. 'In both tariffing and tariffed countries, elevated uncertainty and volatility require robust prudential policies to safeguard financial stability,' the IMF wrote in the report. 'Crucially, the ambiguous and volatile landscape also requires clear and consistent messaging from central banks and the protection of central bank independence, not only in legal terms, but also in practice,' the organization added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store